TFP5, a Peptide Derived from Cdk5 Activator p35, Protects Pancreatic β Cells from Glucose Toxicity
We studied the effect of TFP5 on MIN6 cells (cultured mouse islet β cells) treated with different concentrations of glucose (5 or 25 mM). The results were verified in C57BL/6J mice (control; n=12) and db/db mice with type 2 diabetes mellitus (n=12). To synthesize TFP5, peptide p5 (a derivative of p35 protein, activator of cyclin-dependent kinase 5, Cdk5) was conjugated with a FITC tag at the N-terminus and an 11-amino acid TAT protein transduction domain at the C-terminus. TFP5 was employed to inhibit Cdk5 activity and then to evaluate its efficiency in treating experimental type 2 diabetes mellitus. TFP5 effectively inhibited the pathological hyperactivity of Cdk5, enhanced insulin secretion, and protected pancreatic β cells from apoptosis in vitro and in vivo. In addition, TFP5 inhibited inflammation in pancreatic islets by reducing the expression of inflammatory cytokines TGF-β1, TNFα, and IL-1β. These novel data indicates that TFP5 is a promising candidate for treatment of type 2 diabetes mellitus..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:176 |
|---|---|
| Enthalten in: |
Bulletin of experimental biology and medicine - 176(2023), 1 vom: Nov., Seite 19-25 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, S.-Y. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s10517-023-05959-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054113962 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054113962 | ||
| 003 | DE-627 | ||
| 005 | 20231218064601.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231218s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10517-023-05959-z |2 doi | |
| 035 | |a (DE-627)SPR054113962 | ||
| 035 | |a (SPR)s10517-023-05959-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, S.-Y. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a TFP5, a Peptide Derived from Cdk5 Activator p35, Protects Pancreatic β Cells from Glucose Toxicity |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a We studied the effect of TFP5 on MIN6 cells (cultured mouse islet β cells) treated with different concentrations of glucose (5 or 25 mM). The results were verified in C57BL/6J mice (control; n=12) and db/db mice with type 2 diabetes mellitus (n=12). To synthesize TFP5, peptide p5 (a derivative of p35 protein, activator of cyclin-dependent kinase 5, Cdk5) was conjugated with a FITC tag at the N-terminus and an 11-amino acid TAT protein transduction domain at the C-terminus. TFP5 was employed to inhibit Cdk5 activity and then to evaluate its efficiency in treating experimental type 2 diabetes mellitus. TFP5 effectively inhibited the pathological hyperactivity of Cdk5, enhanced insulin secretion, and protected pancreatic β cells from apoptosis in vitro and in vivo. In addition, TFP5 inhibited inflammation in pancreatic islets by reducing the expression of inflammatory cytokines TGF-β1, TNFα, and IL-1β. These novel data indicates that TFP5 is a promising candidate for treatment of type 2 diabetes mellitus. | ||
| 650 | 4 | |a TFP5 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cdk5 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a insulin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a inflammation factors |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a apoptosis |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Cao, S.-L. |4 aut | |
| 700 | 1 | |a Luo, H.-Y. |4 aut | |
| 700 | 1 | |a Bao, L. |4 aut | |
| 700 | 1 | |a E, J. |4 aut | |
| 700 | 1 | |a Li, B. |4 aut | |
| 700 | 1 | |a Lan, X.-M. |4 aut | |
| 700 | 1 | |a Zhang, G.-Q. |4 aut | |
| 700 | 1 | |a Bao, X. |4 aut | |
| 700 | 1 | |a Zheng, Y.-L. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bulletin of experimental biology and medicine |d Dordrecht [u.a.] : Springer Science + Business Media B. V., 1956 |g 176(2023), 1 vom: Nov., Seite 19-25 |w (DE-627)SPR010703306 |w (DE-600)2037110-X |x 1573-8221 |7 nnns |
| 773 | 1 | 8 | |g volume:176 |g year:2023 |g number:1 |g month:11 |g pages:19-25 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10517-023-05959-z |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 176 |j 2023 |e 1 |c 11 |h 19-25 | ||